ストックスクリーナーアプリを入手
6.03
2.58%
-0.16
アフターアワーズ：
6.03
前日終値:
$6.19
開ける：
$6
24時間の取引高:
1.02M
Relative Volume:
0.84
時価総額：
$306.20M
収益：
$3.64M
当期純損益:
$-87.37M
株価収益率:
-1.4672
EPS:
-4.11
ネットキャッシュフロー:
$-86.46M
1週間 パフォーマンス:
-12.35%
1か月 パフォーマンス:
+7.77%
6か月 パフォーマンス:
+101.67%
1年 パフォーマンス:
-48.90%
1日の値動き範囲:
$5.6789
$6.11
1週間の範囲:
$5.6789
$6.96
52週間の値動き範囲:
$2.10
$13.52
Verastem Inc Stock (VSTM) Company Profile
VSTM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
6.03 | 306.20M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-31 | 繰り返されました | BTIG Research | Buy |
| 2024-09-30 | 開始されました | Guggenheim | Buy |
| 2023-11-21 | 再開されました | BTIG Research | Buy |
| 2023-09-27 | 開始されました | B. Riley Securities | Buy |
| 2023-06-15 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-07 | 再開されました | Alliance Global Partners | Buy |
| 2022-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-03-09 | 開始されました | Truist | Buy |
| 2021-07-01 | 開始されました | Alliance Global Partners | Buy |
| 2021-05-24 | アップグレード | BTIG Research | Neutral → Buy |
| 2019-06-20 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-05-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 開始されました | BTIG Research | Buy |
| 2018-05-02 | 開始されました | Seaport Global Securities | Buy |
| 2018-03-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-13 | 開始されました | Oppenheimer | Outperform |
| 2017-03-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-09-29 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2015-09-29 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | ダウングレード | Mizuho | Buy → Neutral |
| 2015-09-28 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 開始されました | Raymond James | Strong Buy |
| 2015-05-12 | 繰り返されました | UBS | Buy |
| 2015-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2015-01-23 | 繰り返されました | ROTH Capital | Buy |
| 2014-07-08 | 再開されました | Oppenheimer | Perform |
| 2014-02-11 | 開始されました | Mizuho | Buy |
すべてを表示
Verastem Inc (VSTM) 最新ニュース
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade - Yahoo Finance
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Revolutionary Cancer Drug Achieves Complete Response in Colorectal Cancer Study - Stock Titan
Verastem CFO Daniel Calkins sells shares worth $630 - Investing.com India
Verastem CFO Daniel Calkins sells shares worth $630 By Investing.com - Investing.com Australia
H.C. Wainwright lifts Verastem stock price target to $10 By Investing.com - Investing.com Canada
Guggenheim lifts Verastem stock target to $14, maintains buy By Investing.com - Investing.com Canada
H.C. Wainwright lifts Verastem stock price target to $10 - Investing.com India
Royal Bank of Canada Lowers Verastem (NASDAQ:VSTM) Price Target to $14.00 - Defense World
RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating -March 21, 2025 at 08:40 am EDT - Marketscreener.com
BTIG maintains $20 target, Buy rating on Verastem stock By Investing.com - Investing.com Canada
Verastem: Q4 Earnings Snapshot - Midland Daily News
Verastem director Brian Stuglik sells shares worth $4,121 By Investing.com - Investing.com Australia
Verastem Unveils Strategic Plans in New Presentation - TipRanks
Verastem Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Verastem, Inc. SEC 10-K Report - TradingView
Verastem Inc. (VSTM) reports earnings - Quartz
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - Bluefield Daily Telegraph
Verastem director Robert Gagnon sells shares worth $1,973 By Investing.com - Investing.com Australia
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Verastem CEO sells shares worth $1,695 By Investing.com - Investing.com South Africa
Verastem CEO sells shares worth $1,695 - Investing.com
Verastem director Robert Gagnon sells shares worth $1,973 - Investing.com India
Verastem director Brian Stuglik sells shares worth $4,121 - Investing.com
Verastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Verastem Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Verastem to Present at Keystone Symposia on PI3 Kinase - AOL.com
Verastem: Upcoming PDUFA, But I Remain Cautious (NASDAQ:VSTM) - Seeking Alpha
Rhumbline Advisers Acquires 10,352 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion—And the Stocks Leading the Charge - Morningstar
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - The Globe and Mail
Verastem (VSTM) Expected to Announce Earnings on Thursday - Defense World
Objective long/short (VSTM) Report - Stock Traders Daily
Verastem Inc (NASDAQ: VSTM) Stock Forecast: Bearish Expectations Portend -120.34% Downside In 2025 - Stocks Register
Verastem (NASDAQ:VSTM) Stock Price Passes Above 200 Day Moving Average – Should You Sell? - Defense World
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of “Buy” by Brokerages - Defense World
Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Cancer - Marketscreener.com
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Business Wire
Can This New Ovarian Cancer Drug Transform Treatment? Key Data Reveals Breakthrough Potential - Stock Titan
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
When the Price of (VSTM) Talks, People Listen - Stock Traders Daily
Financial Snapshot: Analyzing Verastem Inc (VSTM)’s Key Ratio Metrics - The Dwinnex
Verastem Inc (NASDAQ: VSTM) Shares Fall By -4.77 Percent In The Past Week, But How Long Will It Last? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News
Recent Insider Activity Could Benefit Verastem Inc (VSTM) - Knox Daily
Verastem CEO Dan Paterson sells shares worth $4,890 - MSN
Verastem Inc (VSTM) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):